title: Molecular analysis and long-term follow-up of patients with different forms of 6-pyruvoyl-tetrahydropterin synthase deficiency.
abstract: The outcome of 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency, the most common form of tetrahydrobiopterin (BH4) deficiency, depends on factors such as severity of the disease, type of mutation, time of diagnosis, and mode of treatment. We investigated five patients from four different families, four of them presenting with the severe form of PTPS deficiency and one with the mild peripheral form. In this study, missense (L26F, T67M, P87L, V124L, D136G, D136V) and nonsense (R15-16ins) mutations were detected by reverse transcriptase polymerase chain reaction and sequence analysis. Two patients with the severe form were compound heterozygotes (T67M/P87L and D136G/R15-16ins), two siblings were homozygous for the D136V mutation, and in the patient with the mild form, heterozygous L26F/V124L mutations were present. Two patients are on combined therapy with L-dopa/carbidopa/5-hydroxytryptophan plus BH4, the siblings are on monotherapy with BH4, and the patient with the mild form is now off treatment, presenting with normal plasma phenylalanine levels.
  
  
  CONCLUSIONS
  Long-term follow-up shows that the outcome of 6-pyruvoyl-tetrahydropterin synthase deficiency benefits from treatment started in the first months of life and that the phenotype may change with age. Additionally, depending on the type of mutations, prenatal damage to the fetus may multiply the clinical abnormalities and thus worsen the prognosis of the disease. In patients initially diagnosed with the mild peripheral form of the disease, therapy with tetrahydrobiopterin should be stopped after some time to test whether hyperphenylalaninaemia was only a transient condition.
authors.affiliation: Division of Clinical Chemistry and Biochemistry, University Children's Hospital, Zurich, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Dudesek
authors.forename: W
authors.initials: W
authors.lastname: Röschinger
authors.forename: A C
authors.initials: AC
authors.lastname: Muntau
authors.forename: J
authors.initials: J
authors.lastname: Seidel
authors.forename: D
authors.initials: D
authors.lastname: Leupold
authors.forename: B
authors.initials: B
authors.lastname: Thöny
authors.forename: N
authors.initials: N
authors.lastname: Blau
mesh_terms: D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000378:metabolism / Q000627:therapeutic use; D001708:Biopterins / Q000031:analogs & derivatives / Q000096:biosynthesis; D002230:Carbidopa / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004252:DNA Mutational Analysis; D015259:Dopamine Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D009154:Mutation; D010641:Phenotype; D010661:Phenylketonurias / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D019761:Phosphorus-Oxygen Lyases / Q000172:deficiency* / Q000235:genetics* / Q000378:metabolism; D011622:Pterins / Q000652:urine; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
chemical_list: D000975:Antioxidants; D015259:Dopamine Agents; D011622:Pterins; D001708:Biopterins; D007980:Levodopa; D019761:Phosphorus-Oxygen Lyases; C043497:6-pyruvoyltetrahydropterin synthase; D002230:Carbidopa